Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

TD Cowen analysts trimmed the price target for Eli Lilly and Company (NYSE:LLY) from $1,050 to $960, while reiterating a Buy ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

The Gabelli Growth Fund (GABGX) returned (8.5)% during Q1 of 2025 vs. (10.0)% return for the Russell 1000 Growth Index. Click ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

Three unstoppable megatrends are reshaping the global economy—and one under-the-radar stock is perfectly positioned to profit from all of them. This isn’t a flashy AI stock or a speculative play. It’s ...

An Ozempic warning has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) for any women taking ...

New dementia diagnoses have significantly decreased since 2015, a study published in BMJ found.But more people are living with the disease than ever, underlining “the need for long-term care planning, ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...